AFP and hepatocellular carcinoma: have introduced an innovative prognostic scoring system dubbed “CRAFITY,” anchored in serum CRP and AFP levels, specifically tailored to prognosticate outcomes in HCC patients treated with atezolizumab plus bevacizumab.14